463 related articles for article (PubMed ID: 11005270)
1. Does kidney transplantation normalise cortisol metabolism in apparent mineralocorticoid excess syndrome?
Palermo M; Delitala G; Sorba G; Cossu M; Satta R; Tedde R; Pala A; Shackleton CH
J Endocrinol Invest; 2000; 23(7):457-62. PubMed ID: 11005270
[TBL] [Abstract][Full Text] [Related]
2. Congenital deficiency of 11beta-hydroxysteroid dehydrogenase (apparent mineralocorticoid excess syndrome): diagnostic value of urinary free cortisol and cortisone.
Palermo M; Delitala G; Mantero F; Stewart PM; Shackleton CH
J Endocrinol Invest; 2001 Jan; 24(1):17-23. PubMed ID: 11227727
[TBL] [Abstract][Full Text] [Related]
3. Urinary free cortisone and the assessment of 11 beta-hydroxysteroid dehydrogenase activity in man.
Palermo M; Shackleton CH; Mantero F; Stewart PM
Clin Endocrinol (Oxf); 1996 Nov; 45(5):605-11. PubMed ID: 8977758
[TBL] [Abstract][Full Text] [Related]
4. Role of 11βHSD type 2 enzyme activity in essential hypertension and children with chronic kidney disease (CKD).
Mongia A; Vecker R; George M; Pandey A; Tawadrous H; Schoeneman M; Muneyyirci-Delale O; Nacharaju V; Ten S; Bhangoo A
J Clin Endocrinol Metab; 2012 Oct; 97(10):3622-9. PubMed ID: 22872687
[TBL] [Abstract][Full Text] [Related]
5. The effect of growth hormone replacement therapy on cortisol-cortisone interconversion in hypopituitary adults: evidence for growth hormone modulation of extrarenal 11 beta-hydroxysteroid dehydrogenase activity.
Gelding SV; Taylor NF; Wood PJ; Noonan K; Weaver JU; Wood DF; Monson JP
Clin Endocrinol (Oxf); 1998 Feb; 48(2):153-62. PubMed ID: 9579226
[TBL] [Abstract][Full Text] [Related]
6. A mutation in the cofactor-binding domain of 11beta-hydroxysteroid dehydrogenase type 2 associated with mineralocorticoid hypertension.
Odermatt A; Dick B; Arnold P; Zaehner T; Plueschke V; Deregibus MN; Repetto H; Frey BM; Frey FJ; Ferrari P
J Clin Endocrinol Metab; 2001 Mar; 86(3):1247-52. PubMed ID: 11238516
[TBL] [Abstract][Full Text] [Related]
7. Expression of renal 11beta-hydroxysteroid dehydrogenase type 2 is decreased in patients with impaired renal function.
Quinkler M; Zehnder D; Lepenies J; Petrelli MD; Moore JS; Hughes SV; Cockwell P; Hewison M; Stewart PM
Eur J Endocrinol; 2005 Aug; 153(2):291-9. PubMed ID: 16061836
[TBL] [Abstract][Full Text] [Related]
8. The use of deuterium-labeled cortisol for in vivo evaluation of renal 11beta-HSD activity in man: urinary excretion of cortisol, cortisone and their A-ring reduced metabolites.
Kasuya Y; Shibasaki H; Furuta T
Steroids; 2000 Feb; 65(2):89-97. PubMed ID: 10639020
[TBL] [Abstract][Full Text] [Related]
9. 11beta-hydroxysteroid dehydrogenase activity in proteinuric patients and the effect of angiotensin-II receptor blockade.
Kerstens MN; Buter H; Navis GJ; Dullaart RP
Eur J Clin Invest; 2002 Jul; 32(7):513-8. PubMed ID: 12153552
[TBL] [Abstract][Full Text] [Related]
10. Syndrome of apparent mineralocorticoid excess. A defect in the cortisol-cortisone shuttle.
Stewart PM; Corrie JE; Shackleton CH; Edwards CR
J Clin Invest; 1988 Jul; 82(1):340-9. PubMed ID: 3164727
[TBL] [Abstract][Full Text] [Related]
11. Pediatric renal allograft transplantation does not normalize the increased cortisol/cortisone ratios of chronic renal failure.
Schroth M; Plank C; Rauh M; Dörr HG; Rascher W; Dötsch J
Eur J Endocrinol; 2006 Apr; 154(4):555-61. PubMed ID: 16556718
[TBL] [Abstract][Full Text] [Related]
12. Cortisol metabolism in healthy young adults: sexual dimorphism in activities of A-ring reductases, but not 11beta-hydroxysteroid dehydrogenases.
Finken MJ; Andrews RC; Andrew R; Walker BR
J Clin Endocrinol Metab; 1999 Sep; 84(9):3316-21. PubMed ID: 10487705
[TBL] [Abstract][Full Text] [Related]
13. Tissue-specific Cushing's syndrome, 11beta-hydroxysteroid dehydrogenases and the redefinition of corticosteroid hormone action.
Stewart PM
Eur J Endocrinol; 2003 Sep; 149(3):163-8. PubMed ID: 12943516
[TBL] [Abstract][Full Text] [Related]
14. The role of the 11beta-hydroxysteroid dehydrogenase type 2 in human hypertension.
Ferrari P; Lovati E; Frey FJ
J Hypertens; 2000 Mar; 18(3):241-8. PubMed ID: 10726708
[TBL] [Abstract][Full Text] [Related]
15. Furosemide and 11beta-hydroxysteroid dehydrogenase activity, in man.
Palermo M; Armanini D; Shackleton CH; Sorba G; Cossu M; Roitman E; Scaroni C; Delitala G
Exp Clin Endocrinol Diabetes; 2002 Sep; 110(6):272-6. PubMed ID: 12373630
[TBL] [Abstract][Full Text] [Related]
16. Hypoxia causes down-regulation of 11 beta-hydroxysteroid dehydrogenase type 2 by induction of Egr-1.
Heiniger CD; Kostadinova RM; Rochat MK; Serra A; Ferrari P; Dick B; Frey BM; Frey FJ
FASEB J; 2003 May; 17(8):917-9. PubMed ID: 12626438
[TBL] [Abstract][Full Text] [Related]
17. [A case of apparent mineralocorticoid excess caused by type 2 11 beta- hydroxysteroid dehydrogenase deficiency].
Morineau G; Pascoe L; Marc JM; Caillette A; Krozowski Z; Corvol P; Fiet J
Arch Mal Coeur Vaiss; 1997 Aug; 90(8):1111-5. PubMed ID: 9404418
[TBL] [Abstract][Full Text] [Related]
18. Urinary cortisol to cortisone metabolites in hypertensive obese children.
Csábi GY; Juricskay S; Molnár D
J Endocrinol Invest; 2000; 23(7):435-9. PubMed ID: 11005267
[TBL] [Abstract][Full Text] [Related]
19. 11β-Hydroxysteroid dehydrogenase type-2 and type-1 (11β-HSD2 and 11β-HSD1) and 5β-reductase activities in the pathogenia of essential hypertension.
Campino C; Carvajal CA; Cornejo J; San Martín B; Olivieri O; Guidi G; Faccini G; Pasini F; Sateler J; Baudrand R; Mosso L; Owen GI; Kalergis AM; Padilla O; Fardella CE
Endocrine; 2010 Feb; 37(1):106-14. PubMed ID: 19882252
[TBL] [Abstract][Full Text] [Related]
20. Apparent mineralocorticoid excess syndromes.
Shimojo M; Stewart PM
J Endocrinol Invest; 1995; 18(7):518-32. PubMed ID: 9221270
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
